A label free chemoproteomic-based platform to disclose cannabidiol molecular mechanism of action on chronic myelogenous leukemia cancer cells.

Abstract

The discovery of the interactome of cannabidiol (CBD), a non-psychoactive cannabinoid from Cannabis sativa L., has been here performed on chronic myelogenous leukemia cancer cells, using an optimized chemo-proteomic stage, which links Drug Affinity Responsive Target Stability with Limited Proteolysis Multiple Reaction Monitoring approaches. The obtained results showed the ability of CBD to target simultaneously some potential protein partners, corroborating its well-known poly-pharmacology activity. In human chronic myelogenous leukemia K562 cancer cells, the most fascinating protein partner was identified as the 116 kDa U5 small nuclear ribonucleoprotein element called EFTUD2, which fits with the spliceosome complex. The binding mode of this oncogenic protein with CBD was clarified using mass spectrometry-based and in silico analysis.

• Authors: Sara Ceccacci, Lorenzo Corsi, Lucio Spinelli, Clarissa Caroli, Matilde Marani, Lisa Anceschi, Matteo Mozzicafreddo, Federica Pellati, Maria Chiara Monti
• Journal: Heliyon (Heliyon) Vol. 10 Issue 1 Pg. e24196 (Jan 15 2024) ISSN: 2405-8440 [Print] England
• PMID: 38268604 (Publication Type: Journal Article)
• Copyright: © 2024 The Authors.